RSBY

RSBY.org is a cardiometabolic standards initiative that turns routine labs into clear, outcome-oriented targets. Built around Tirzepatide and internal-medicine practice, RSBY links four pivotal biomarkers—apoB, hs-CRP, ALT, and NT-proBNP—to the expected clinical yield you can achieve in real patients: fewer atherosclerotic events, lower systemic inflammation, improved metabolic-liver health, and better cardiac function.

​

What We Standardize

​

• apoB: atherogenic lipoprotein burden → targets tied to ASCVD risk reduction.

• hs-CRP: systemic inflammation → thresholds aligned with event risk and response.

• ALT: metabolic-liver signal → goals that track NAFLD/NASH improvement.

• NT-proBNP: cardiac stress → ranges linked to HF risk and symptom change.​

​

How it works

​

Evidence-linked targets: Each biomarker has consensus ranges anchored to outcome data.

​

Yield bands: “Expected Clinical Yield” tiers (e.g., modest / meaningful / high) connect biomarker movement and weight/A1C response on tirzepatide to cardiometabolic endpoints.

​

Point-of-care tools: Calculators, titration “yardsticks,” and deprescribing cues for everyday internal-medicine workflows.

Living updates: A continuously refreshed brief reviews new trials, registries, and safety signals.

​

Who it’s for

​

Internists, cardiologists, endocrinologists, hepatologists, hospitalists, and primary-care teams who want a single, disciplined standard to guide tirzepatide-centric care—plus researchers and payors who need auditable targets and KPIs.

 

Why now

​

Incretin-based therapy is reshaping cardiometabolic medicine. RSBY gives the field a common language: measure what matters, aim for defined ranges, and quantify the yield—so weight loss, A1C change, and biomarker shifts translate into fewer events, better quality of life, and smarter medication use.

 

Our aim

 

Practical, forward-looking, and transparent. RSBY.org exists to help clinicians and systems move from scattered thresholds to reference standards—so every lab value is a lever toward measurable, patient-centered outcomes.